Ann Optom Contact Lens.  2023 Dec;22(4):133-137. 10.52725/aocl.2023.22.4.133.

Efficacy of Subconjunctival Bevacizumab Injection after Pterygium Excision with Limbal Conjunctival Autograft in Recurred Pterygium

• Lee JY
• Yoo YJ
• Han SB

• KMID: 2549397
• DOI: http://doi.org/10.52725/aocl.2023.22.4.133

Abstract

Purpose
To evaluate the efficacy and safety of subconjunctival bevacizumab injection after pterygium excision with limbal conjunctival autograft and limbal fixation suture in recurred pterygium.
Methods
We retrospectively reviewed the medical records of 9 patients (11 eyes) who received subconjunctival bevacizumab injection after pterygium excision with limbal conjunctival autograft and limbal fixation suture for recurred pterygium. All patients included in this study completed follow-up for at least 12 months. Demographic variables, postoperative clinical outcomes, and recurrence rate were analyzed. Recurrence of pterygium was evaluated at 12 months after surgery.
Results
The study subjects comprised 5 male patients (5 eyes) and 4 female patients (6 eyes) with a mean age of 66.0 ± 13.0 years (range 43-78 years). Among the 11 eyes, no recurrence occurred after the follow-up period of 12 months.
Conclusions
Subconjunctival bevacizumab injection after pterygium excision with limbal conjunctival autograft and limbal fixation suture appears to be an effective method of preventing the recurrence in recurred pterygium.

Keyword

Bevacizumab; Pterygium; Vascular endothelial growth factor A